{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Cancer+%28MBC%29&page=3", "query": { "condition": "Metastatic Breast Cancer (MBC)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 108, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Cancer+%28MBC%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Breast+Cancer+%28MBC%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T16:33:06.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01160211", "title": "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 369, "start_date": "2011-05-05", "completion_date": "2022-06-06", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 4, "location_summary": "Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01160211" }, { "nct_id": "NCT00320385", "title": "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 296, "start_date": "2005-11", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2016-02-26", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 87, "location_summary": "Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Highland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320385" }, { "nct_id": "NCT04072952", "title": "A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Vepdegestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Estrogen Receptor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2019-09-22", "completion_date": "2026-03-05", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 16, "location_summary": "Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04072952" }, { "nct_id": "NCT05654532", "title": "Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AC699", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accutar Biotechnology Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-12-29", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 9, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05654532" }, { "nct_id": "NCT06377852", "title": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 500, "start_date": "2024-10-29", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 88, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377852" }, { "nct_id": "NCT06855654", "title": "Promoting Resilience in Women With Breast Cancer (PRISM -MBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Promoting Resilience in Women with Breast Cancer (PRISM)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-01-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Chapel Hill, North Carolina", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855654" }, { "nct_id": "NCT01745367", "title": "Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Tivozanib Hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2012-11", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01745367" }, { "nct_id": "NCT04498481", "title": "TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2018-03-01", "completion_date": "2018-07-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04498481" }, { "nct_id": "NCT00567879", "title": "A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 56, "start_date": "2008-04", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2016-05-09", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Norwalk, Connecticut + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567879" }, { "nct_id": "NCT02001974", "title": "Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Paclitaxel+Reparixin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 33, "start_date": "2012-02-27", "completion_date": "2015-01-15", "has_results": true, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-10-09T16:33:06.543Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Fairway, Kansas • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02001974" } ] }